Trial Information
Current as of August 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Capillary OGTT Study is looking to find out if a new way of testing for Type 1 Diabetes (T1D) can be done at home instead of in a hospital. Currently, the test requires a needle in the arm and multiple blood samples taken over a few hours, which can be uncomfortable. This study will see if a simpler method using a finger-prick blood test, called GTT@home, can work just as well. Participants will drink a sugary drink and then provide a drop of blood before and two hours after. The study will also explore using a continuous glucose monitor (CGM) that checks glucose levels through the skin.
To take part in the study, participants need to be under 18 years old and either already undergoing an oral glucose tolerance test (OGTT) or at risk for T1D. Some children with T1D will be invited to wear the CGM to see how it compares to the finger-prick test. The study aims to recruit 90 children and young people, and those involved will be asked about their experiences with testing. This research could help determine if testing at home could become a routine practice for managing T1D.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Cohort 1
- • Willing and able to give informed consent for participation, or assent with parental consent
- • Aged \< 18 years old
- • Able to consume oral glucose drink within 10 minutes
- • Undergoing an OGTT, or consent to have one
- • Cohort 2
- • Positive for two or more islet autoantibodies at any time
- • Willing and able to give informed consent for participation, or assent with parental consent
- • Aged \< 18 years old
- • Able to consume oral glucose drink within 10 minutes
- • CGM sub-study
- • Willing and able to give informed consent for participation, or assent with parental consent
- • Aged \< 18 years old
- • Able to consume oral glucose drink within 10 minutes
- • Confirmed to have stage 1, 2 or 3 T1D
- • Participation in Cohort 1
- • Qualitative sub-study
- • Willing and able to give informed consent for participation, or assent with parental consent Then EITHER
- • A young person positive for two or more islet autoantibodies (15 years old and above) at any time, or parent of a young person who has experienced a metabolic test e.g. OGTT OR
- • A healthcare professional involved in delivering metabolic testing
- Exclusion Criteria:
- • Cohort 1
- • Any known haemoglobinopathy
- • Cystic fibrosis related diabetes
- • Non-English speaker
- • Cohort 2
- • Any known haemoglobinopathy
- • Known clinical diabetes and on treatment
- • Non-English speaker
- • No recent weight available (within 3 months of study visit) and unable to obtain new weight measurement
- • CGM sub-study
- • Any known haemoglobinopathy
- • Cystic fibrosis related diabetes
- • Non-English speaker
- • Any active skin issue which would prevent the use of a CGM device
- • Qualitative sub-study
- • • Non-English speaker
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, , United Kingdom
Nottingham, , United Kingdom
Cardiff, , United Kingdom
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported